Role of Magnesium in the Failure of RhDNase Therapy in Patients with Cystic Fibrosis

Overview

Journal Thorax

Date 2006 Oct 31

PMID 17071834

Citations 16

Authors

N N Sanders

H Franckx

K De Boeck

J Haustraete

S C De Smedt

J Demeester

Affiliations

Soon will be listed here.

Abstract

Background: In the management of cystic fibrosis (CF), rhDNase-I inhalation is widely used to facilitate the removal of the highly viscous and elastic mucus (often called sputum) from the lungs. However, an important group of CF patients does not benefit from rhDNase-I treatment. A study was undertaken to elucidate the reason for the failure of rhDNase-I in these patients and to evaluate strategies to overcome this.

Methods: The biochemical properties, physical properties, and degradation by rhDNase-I of sputum obtained from clinical responders and non-responders to rhDNase-I were compared, and the ability of magnesium to reactivate rhDNase-I in DNA solutions and in sputum was investigated. The effect of oral magnesium supplements on magnesium levels in the sputum of patients with CF was also examined.

Results: Sputum from clinical responders was extensively degraded in vitro on incubation with rhDNase-I, while sputum from clinical non-responders was not degraded: the median decrease in sputum elasticity in the two groups was 32% and 5%, respectively. Sputum from clinical responders contained significantly higher concentrations of magnesium than sputum from non-responders (2.0 mM v 1.3 mM; p = 0.020). Sputum that could not be degraded by rhDNase-I became degradable after preincubation with magnesium. The effect of magnesium on rhDNase-I activity was mediated through actin. Oral intake of magnesium enhanced the magnesium concentration in the sputum of CF patients.

Conclusion: Increasing the magnesium concentration in sputum by, for example, oral magnesium supplements may be a promising new strategy to overcome the failure of rhDNase-I in patients with CF.

Citing Articles

Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.

Murphy R, Pizzato J, Cuthbertson L, Sabnis A, Edwards A, Nolan L NPJ Antimicrob Resist. 2025; 2(1):4.

PMID: 39843948 PMC: 11702655. DOI: 10.1038/s44259-024-00022-x.

Widespread fungal-bacterial competition for magnesium lowers bacterial susceptibility to polymyxin antibiotics.

Hsieh Y, Sun W, Young J, Cheung R, Hogan D, Dandekar A PLoS Biol. 2024; 22(6):e3002694.

PMID: 38900845 PMC: 11218974. DOI: 10.1371/journal.pbio.3002694.

Fractional Exhalation Nitric Oxide (FeNO) changes in cystic fibrosis patients induced by compound honey syrup: a pretest-posttest clinical trial.

Sadr S, Tahermohammadi H, Kaveh S, Khanbabaee G, Tabatabaei S, Choopani R BMC Pulm Med. 2023; 23(1):488.

PMID: 38053097 PMC: 10696786. DOI: 10.1186/s12890-023-02787-9.

Update on the management of vitamins and minerals in cystic fibrosis.

Sankararaman S, Hendrix S, Schindler T Nutr Clin Pract. 2022; 37(5):1074-1087.

PMID: 35997322 PMC: 9544449. DOI: 10.1002/ncp.10899.

Mucoid Pseudomonas aeruginosa Can Produce Calcium-Gelled Biofilms Independent of the Matrix Components Psl and CdrA.

Jacobs H, ONeal L, Lopatto E, Wozniak D, Bjarnsholt T, Parsek M J Bacteriol. 2022; 204(5):e0056821.

PMID: 35416688 PMC: 9112934. DOI: 10.1128/jb.00568-21.

References

Swain R . Magnesium for the next millennium. South Med J. 1999; 92(11):1040-7. DOI: 10.1097/00007611-199911000-00001. View

Larhed A, Artursson P, Grasjo J, Bjork E . Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci. 1997; 86(6):660-5. DOI: 10.1021/js960503w. View

Cobos N, Danes I, Gartner S, Gonzalez M, Linan S, Arnau J . DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr. 2000; 159(3):176-81. DOI: 10.1007/s004310050046. View

Bollert F, Paton J, Marshall T, Calvert J, Greening A, Innes J . Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. Eur Respir J. 2000; 13(1):107-13. DOI: 10.1183/09031936.99.13105399. View

Sanders N, De Smedt S, Van Rompaey E, Simoens P, De Baets F, Demeester J . Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med. 2000; 162(5):1905-11. DOI: 10.1164/ajrccm.162.5.9909009. View

Halmerbauer G, Arri S, Schierl M, Strauch E, Koller D . The relationship of eosinophil granule proteins to ions in the sputum of patients with cystic fibrosis. Clin Exp Allergy. 2000; 30(12):1771-6. DOI: 10.1046/j.1365-2222.2000.00988.x. View

Zahm J, Debordeaux C, Maurer C, Hubert D, Dusser D, Bonnet N . Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions. Am J Respir Crit Care Med. 2001; 163(5):1153-7. DOI: 10.1164/ajrccm.163.5.2005002. View

Guggino W . Cystic fibrosis salt/fluid controversy: in the thick of it. Nat Med. 2001; 7(8):888-9. DOI: 10.1038/90914. View

El Hassan N, Chess P, Huysman M, Merkus P, de Jongste J . Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics. 2001; 108(2):468-70. DOI: 10.1542/peds.108.2.468. View

10.

Konstan M, Berger M . Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997; 24(2):137-42; discussion 159-61. DOI: 10.1002/(sici)1099-0496(199708)24:2<137::aid-ppul13>3.0.co;2-3. View

11.

Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K . The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest. 1998; 102(1):15-21. PMC: 509060. DOI: 10.1172/JCI2729. View

12.

Adams J, Conway S, Wilson C . Hypomagnesaemic tetany associated with repeated courses of intravenous tobramycin in a patient with cystic fibrosis. Respir Med. 1998; 92(3):602-4. DOI: 10.1016/s0954-6111(98)90319-5. View

13.

Harms H, Matouk E, Tournier G, von der Hardt H, Weller P, Romano L . Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group. Pediatr Pulmonol. 1998; 26(3):155-61. DOI: 10.1002/(sici)1099-0496(199809)26:3<155::aid-ppul1>3.0.co;2-k. View

14.

Sheppard D, Welsh M . Structure and function of the CFTR chloride channel. Physiol Rev. 1999; 79(1 Suppl):S23-45. DOI: 10.1152/physrev.1999.79.1.S23. View

15.

Chen B, Costantino H, Liu J, Hsu C, Shire S . Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J Pharm Sci. 1999; 88(4):477-82. DOI: 10.1021/js980273g. View

16.

Akbar A, Rees J, Nyamugunduru G, English M, Spencer D, Weller P . Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr. 1999; 88(7):783-5. DOI: 10.1080/08035259950169116. View

17.

Yuta A, Baraniuk J . Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep. 2005; 5(3):243-51. DOI: 10.1007/s11882-005-0044-6. View

18.

Suri R . The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs. 2005; 19(3):135-44. DOI: 10.2165/00063030-200519030-00001. View

19.

Xia B, Royall J, Damera G, Sachdev G, Cummings R . Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis. Glycobiology. 2005; 15(8):747-75. DOI: 10.1093/glycob/cwi061. View

20.

Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J . Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005; 128(1):337-44. DOI: 10.1378/chest.128.1.337. View